Construction starts at Cell Therapy Catapult’s £55m cell and gene therapy manufacturing centre

Published: 18-Nov-2015
Design & Build Pharmaceutical Cell & Gene Therapy

Turf cut on new 7,200 square metre facility in Stevenage, UK

The Cell Therapy Catapult, a UK organisation dedicated to the growth of the UK cell and gene therapy industry, has announced the official start of construction for its 7,200m2 cell and gene therapy manufacturing centre.

John Brown, Chairman of the Cell Therapy Catapult, marked the beginning of building work at a groundbreaking ceremony on the site attended by representatives from academia, healthcare, regulatory and industry interests across the advanced therapy sectors.

The Cell Therapy Catapult manufacturing centre is due to be completed and opened in Stevenage in 2017. Its proximity to international air transport links at London Heathrow airport will enable time critical transport of the cells of patients to and from the facility.

Innovate UK, the UK’s innovation agency, has committed £55m to the Cell Therapy Catapult for the creation of the centre. It will generate up to 150 specialist jobs, and many more additional roles in the cluster that grows around it. The UK government and Cell Therapy Catapult also anticipate that the centre will attract considerable inward investment to the UK.

The Cell Therapy Catapult cell and gene therapy manufacturing centre will be the world’s first facility of its kind

'The Cell Therapy Catapult cell and gene therapy manufacturing centre will be the world’s first facility of its kind. I am very proud that it will be built in the UK,' said George Freeman, MP, UK Government Minister for Life Sciences.

'The UK is at the leading edge of the cell and gene therapy industry, with a disproportionate share of both world leading scientists and new developments in the field. It will also contribute to considerable additional inward investment to the UK. This has created an advantage upon which the country has to continue to capitalise. The centre will contribute to the development of a large scale industry in the UK and the development of a cell and gene therapy cluster that will deliver both health and wealth to the UK.'

Keith Thompson, CEO, the Cell Therapy Catapult, said: 'The manufacturing centre will be a game changer for the UK cell therapy industry, as well as the future international availability of therapies for patients. Both UK and international companies will now be able to plan and spread costs via economies of scale for their manufacturing for clinical trials for the UK, European and global markets.'

  • Companies:
  • Innovate UK
  • Cell and Gene Therapy Catapult
See more

You may also like

Design & Build

InnovateUK funnels $10m into UK microelectronics infrastructure

Read more
Custom Interconnect has been supported by the investment to add 46,000 sqft to its facility, including a 15,000 sqft ISO Class 7 cleanroom

Trending Articles

  1. What is ISO 8 cleanroom classification? Each cleanroom class is denoted by a maximum concentration of particles per cubic meter or cubic foot of air. ISO 8 is the second lowest cleanroom classification
  2. Hodess builds ISO Class 8 cleanroom for electronic packaging specialist Remtec US-based Hodess Cleanroom Construction has built Remtec a new $12m cleanroom in Canton, Massachusetts, US
  3. Guardtech and Elis: Taking over a cleanroom laundry build mid-project Originally contracted to develop just the cleanroom, Joe Shackley from Guardtech talks about taking the cleanroom laundry build after the original Principal Contractor was unable to fulfil the requirements
  4. The importance of growth promotion testing Given the critical nature of microbiological quality tests which are employed to ensure that pharmaceutical products are safe for human use, it is in turn essential to undertake quality control (QC) tests to ensure that the culture media being used for these is fit for purpose and performs properly. Cherwell Laboratories' Steven Brimble explains
  5. Airkey USP 797&800 FastIns Modular Cleanroom project case study In the pharmaceutical industry, GMP has always been the primary reference standard for building and operating clean rooms all over the world. In recent years however, the USP 797 and USP 800 have reshaped and set very high standards for the handling process of sterile compounding for non-hazardous or hazardous drugs in details, making them another priority roadmap in building pharmaceutical cleanroom

Upcoming event

Pharmig Annual Pharmaceutical Microbiology Conference

20–21 November 2024 | Conference | Nottingham, UK See all

You may also like

Design & Build

InnovateUK funnels $10m into UK microelectronics infrastructure

Custom Interconnect has been supported by the investment to add 46,000 sqft to its facility, including a 15,000 sqft ISO Class 7 cleanroom
Media

British cell and gene therapy accelerator releases annual report

The CGT Catapult has worked on more than 110 projects addressing industry challenges
Pharmaceutical

CGT Catapult and pHion Therapeutics join forces

British companies promote the RALA gene therapy delivery method to the immunotherapy market
Regulatory

Cell and Gene Therapy Catapult centre gets green light

The independent cell and gene therapy researcher and industry partner, working with Innovate UK, has been granted new licences to progress its biomedical research
Manufacturing

CGT Catapult collaborates with Freeline Therapeutics

Cell and Gene Therapy Catapult (CGT Catapult) has teamed up with Freeline Therapeutics to further develop its proprietary manufacturing platform at CGT Catapult’s large scale GMP manufacturing centre in Stevenage, UK
Design & Build

New funds for UK Cell & Gene Therapy Catapult manufacturing centre

An extra £12m funding will double the current capacity of the Cell and Gene Therapy Catapult manufacturing centre in Stevenage
Pharmaceutical

Thermo Fisher Scientific collaborates with UK Cell and Gene Therapy Catapult

The company will help with manufacturing capability and distribution, logistics, and storage capacity
Subscribe now